This meeting was organised and funded by Novartis Pharmaceuticals Ltd. and is classed as promotional under the Association of the British Pharmaceutical Industry (ABPI) Code.
The Haematology Masterclass is a multidisciplinary educational programme that brings together global haematology expertise to provide high-quality and timely educational content. Running for the past 7 years, the Masterclass has become a well-respected forum for haematology healthcare professionals to share the latest clinical trial data and specialist experience from clinical practice.
The 2-day event in 2022 was a hybrid programme with expert speakers and chairs holding a combination of live and pre-recorded presentations, case studies, open discussion and breakout sessions. The focus topics included sickle cell disease (SCD), immune thrombocytopenia (ITP), chronic myeloid leukaemia (CML), myeloproliferative neoplasms (MPNs) and the use of CAR-T therapy in lymphoma and acute lymphoblastic leukaemia (ALL). The meeting closed with a special plenary on encouraging patient engagement in haematology services, with a final discussion on the recent post-pandemic shift to increasingly remote management in haematology services, and the advantages and limitations of this regarding patient engagement.
Feedback was positive, with all involved finding that the 2022 Masterclass championed Novartis’ objective to support healthcare professionals in the future delivery of improved patient care for challenging haematological conditions.
For an overview of the future of patient care in haematology, please click on the presentation links below.
After viewing a video, you will be eligible to receive your CPD certificate.
In order to do so, please complete the steps below:
- View a video presentation below and watch until the end.
- After 100% completion, a pop-up will appear to enable you to download your CPD certificate for each respective presentation.
Prescribing information links can be found underneath each video recording.
Session 1: SCD Plenary 1
Dr Julie Kanter distils her real-world experience in the US to provide practical advice on how to optimise use of ADAKVEO▼ (crizanlizumab) to prevent VOCs. ADAKVEO has a conditional marketing authorisation and further evidence is awaited.
Dr Julie Kanter
Session 1: SCD Plenary 2
What can the MDT do to help facilitate delivery of novel therapies in the NHS? Professor Paul Telfer gives his expert view.
Professor Paul Telfer
Session 1: SCD case study
Every patient is unique. Dr Joe Sharif talks about two particularly challenging case studies of patients with SCD.
Dr Joe Sharif
Session 2: ITP Plenary 1
Dr Drew Provan takes a look at how ITP treatment goals and the role of immunosuppression have changed over the past 2 years.
Session 2: ITP Plenary 2
Dr Suthesh Sivapalaratnam describes how genomics will assist in the modern day management of ITP.
Dr Suthesh Sivapalaratnam
Session 2: ITP case study
Dr Gillian Lowe and Dr Clare Rees discuss COVID-19 infection in an unvaccinated ITP patient and COVID-19 vaccination in another patient with ITP.
Dr Gillian Lowe, Dr Clare Rees
Session 3: CML Plenary 1
Dr Nauman Butt considers the implications of managing a modern CML service.
Session 3: CML case study (1)
Dr Kate Rothwell presents a case study which explores the management of CML patients who risk AP or BC progression.
Dr Kate Rothwell
Session 3: CML case study (2)
Professor Susan Branford covers state-of-the-art monitoring of CML in her case study.
Professor Susan Branford
Session 4: MPN Plenary 1
Dr Joanne Ewing explores how important symptom management is in MF.
Dr Joanne Ewing
Session 4: MPN Plenary 2
Professor Francesca Palandri discusses how treatment efficacy can be optimised for MF patients.
Professor Francesca Palandri
Session 4: MPN Case study
Professor Srdan Verstovsek profiles a case study to pose the question; can you improve overall survival in MF?
Professor Srdan Verstovsek
Session 5: CAR-T Plenary 1
Dr Gloria Iacoboni provides learnings from CAR-T therapy roll-out over the past 3 years.
Dr Gloria Iacoboni
Session 5: CAR-T Case study
Dr Rod Johnson provides a case study on optimising the DLBCL patient pathway in CAR-T therapy and beyond.
Thank you for taking the time to watch the presentations
Novartis is truly committed to providing world-class education to our healthcare professionals. We recognise the value this meeting brings to a wide range of healthcare professionals including registrars, nurses, pharmacists and consultants.
We hope that you can join us for our next meeting in 2023.
AP, accelerated phase; BC, blast crisis; CAR-T, chimeric antigen receptor T-cell; CML, chronic myeloid leukaemia; CPD, continuing professional development; DLBCL, diffuse large B cell lymphoma; ITP, immune thrombocytopenia; MDT, multidisciplinary team; MF, myelofibrosis; MPN, myeloproliferative neoplasm; SCD, sickle cell disease; VOC, vaso-occlusive crisis.